相关实验视频
Updated: Jun 14, 2025

08:50
Prostaglandin Extraction and Analysis in Caenorhabditis elegans
Published on: June 25, 2013
19.5K
在FDA不良事件报告系统数据库中通过数据挖掘检测前列腺素类似物信号
Homero Contreras-Salinas1, María Soledad Romero-López2, Oscar Olvera-Montaño3
1Pharmacovigilance Department, Laboratorios Sophia SA de CV, Zapopan, Jalisco, Mexico homero.contreras@sophia.com.mx.
BMJ open ophthalmology
|August 29, 2024
概括
眼科前列腺素类似物可能与严重的不良事件有关,例如恶性中瘤和糖尿病. 需要进一步的研究来证实眼滴药物的这些潜在安全信号.
科学领域:
- 药监和药物安全 药监和药物安全
- 眼科医生 眼科 眼科
- 数据挖掘和生物统计学
背景情况:
- 眼科前列腺素类似物广泛用于青光眼的治疗.
- 识别潜在的安全信号对于患者的福祉至关重要.
- 食品和药物管理局的不良事件报告系统 (FAERS) 是药物监督的一个关键资源.
研究的目的:
- 检测与眼科前列腺素类似物相关的潜在安全信号.
- 分析特定前列腺素药物的FAERS数据库中的不良事件数据.
主要方法:
- 进行了FAERS数据库的数据挖掘.
- 采用了统计方法,包括比例报告比率,报告OR,贝叶斯信心传播神经网络,信息组件0.25和千平方.
- 分析的重点是latanoprost,travoprost,tafluprost和bimatoprost. 这三种药物是最常见的.
主要成果:
- 12个首选术语在统计学上与眼科前列腺素类似物有关.
- 值得注意的关联包括糖尿病,低音,恶性中瘤,免疫球蛋白E升高,白内障,白内障,血,异常血细胞计数,皮肤脱皮,胸部不适和口腔干燥.
- 具体事件的数量从1到2不等.
结论:
- 眼科前列腺素类似物和几个不良事件之间存在潜在的关系,这是由生物可信性支持的.
- 值得关注的事件包括恶性中瘤,异常血清,高免疫球蛋白E,糖尿病,白内障,白内障,胸部不适和口腔干燥.
- 需要进一步的研究来证实或反驳这些安全信号,并确定潜在的药物事件关联.
相关概念视频
Pharmacovigilance
789
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
789
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
375
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
375
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160

